BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Inborn Errors of Metabolism Clinical Trial

Official title:

Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT03639844
• Other study ID #: BP-C-004
• Status: No longer available

Study information

• Verified date: October 2020
• Source: Bellicum Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.

Description:

This is an expanded access protocol of BPX-501 T cells infused after T cell-depleted HSCT in pediatric patients with non-malignant hematologic disorders eligible for treatment on the BP-U-004 study.

The purpose of this protocol is to provide access to the CaspaCIDe system combination product (BPX-501 gene modified T cells and rimiducid) to patients on a case by case basis who do not meet the BP-U-004 protocol eligibility criteria. BPX-501 infusion can enhance immune reconstitution with the potential for reducing the severity and duration of severe acute GVHD.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: 3 Months to 21 Years

Eligibility

Inclusion Criteria:

1. Males or females

2. Age < 21 years and > 3 months

3. Life expectancy > 10 weeks

4. Patients deemed eligible for allogeneic stem cell transplantation.

5. Non-malignant disorders including:

1. inherited metabolic disorders such as adrenal leukodystrophy;

2. lysosomal storage disorders such as Hurler syndrome or metachromatic leukodystrophy

3. other inborn errors of metabolism

6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative evaluated using high resolution molecular typing).

7. A minimum genotypic identical match of 5/10 is required.

8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.

9. Lansky/Karnofsky score > 50

10. Signed written informed consent

3.2 Subject exclusion criteria

1. Age < 3 months or >21 years

2. Patients with non-malignant disorders eligible for treatment on the BP-U-004 study:

1. primary immune deficiencies,

2. severe aplastic anemia not responding to immune suppressive therapy,

3. osteopetrosis,

4. selected cases of hemoglobinopathies and

5. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML)

3. Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion

4. Patient receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion

5. Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 ml / min)

6. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)

7. Current active infectious disease (including positive HIV serology or viral RNA)

8. Serious concurrent uncontrolled medical disorder

9. Pregnant or breast feeding female patient

10. Lack of parents'/guardian's informed consent.

-

Related Conditions & MeSH terms

• Disease
• Hurler Syndrome
• Inborn Errors of Metabolism
• Inherited Metabolic Disorder
• Leukodystrophy, Metachromatic
• Lysosomal Storage Diseases
• Lysosomal Storage Disorder
• Metabolic Diseases
• Metabolism, Inborn Errors
• Metachromatic Leukodystrophy
• Mucopolysaccharidosis I

Intervention

Biological:
• rivogenlecleucel
BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.

Drug:
• rimiducid
Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD

Locations

Country	Name	City	State
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Bellicum Pharmaceuticals

Country where clinical trial is conducted

United States,